A judge in the longstanding patent dispute between medical device makers Fresenius Medical Care Holdings Inc. and Baxter International Inc. has denied Fresenius’ motion to stay the case pending reexamination of the patents-in-suit by the U.S. Patent and Trademark Office.
A conflicted federal trade agency on Thursday banned the importation of mobile phones, personal digital assistants and other handheld devices which contain Qualcomm Inc. chips into the U.S, but limited the ban to new models which had not previously been introduced for sale in the country.
Despite the recent legal troubles Google Inc. has experienced because of its Book Search project, the search engine giant revealed Wednesday that it would digitize up to 10 million books with the Committee on Institutional Cooperation.
In a suit that could affect every cell phone released over the last few years, a patent-holding company accused all the big players in the cellular industry on Wednesday of infringing on its patent for a “mobile entertainment and communication device.”
A judge has dismissed a patent case brought by a unit of Johnson & Johnson and its partner Merck & Co. alleging that Perrigo Co. infringed a patent used in the formulation of Pepcid Complete.
A one-time in-house counsel for telecommunications giant Motorola Inc. has moved to Howrey LLP's intellectual property group, leaving Brinks, Hofer, Gilson & Lione.
The Patent Reform Act of 2007 came before the House Judiciary Committee on Wednesday, fueling the ongoing controversy over how to best reform U.S. patent laws.
A group of consumers and unions have reiterated their battle cry for the nation's highest court to take up the tamoxifen citrate antitrust litigation, arguing that the case presents “a straightforward opportunity” to weigh in on the legal issues surrounding authorized generics.
Cordis Corp. fired back on Tuesday to a suit in which Medtronic Inc. accused it of infringing two patents for coronary stents, arguing that the two patents at issue are unenforceable due to inequitable conduct.
A patent holding company has dismissed claims against Hewlett-Packard Co., Tivo Inc., and Sanyo North American Corp. for allegedly infringing a patent for digital television receivers.
In an effort to expand its transactional and patent prosecution experience and abilities, intellectual property boutique law firm Woodcock Washburn LLP has added three new partners and an associate to its Atlanta office, the firm said Wednesday.
Rembrandt Technologies LP received a boost Tuesday in its patent infringement suit against Comcast Corp. when a judge favored broad construction of the claims in four disputed patents, as Rembrandt had asked.
A third defendant has been sentenced to two years in prison for conspiring to steal trade secrets from the Coca-Cola Co. and sell them to rival PepsiCo Inc.
Comcast has filed a trademark infringement lawsuit against Qwest Communications International Inc. saying Qwest's claim that its Internet service is faster that Comcast's is intentionally deceptive.
Software maker Oracle Corp. has added copyright infringement and breach of contract claims to a computer theft lawsuit it brought in March against German archrival SAP AG.
A federal judge on Friday agreed to allow Watson Pharmaceuticals Inc. and Sun Pharmaceutical Industries Ltd. to seek attorneys' fees in an infringement suit brought by Novartis Pharmaceuticals Corp. over patents for Exelon, the Swiss drug maker’s Alzheimer’s treatment.
McDermott Will & Emery LLP has raided Dorsey & Whitney LLP to bolster the intellectual property practice in its Silicon Valley office.
Technology company GraphOn Corp. filed suit Thursday against Juniper Networks Inc., claiming its Silicon Valley rival’s products infringe GraphOn patents covering security and firewall technology.
A circuit court on Tuesday reaffirmed that a Pfizer Inc. patent for popular hypertension drug Norvasc is invalid by overturning a patent infringement ruling against Mylan Laboratories Inc.
Pfizer Inc. has asked the nation's highest court to expedite its bid for a writ of certiorari in its patent feud with Apotex Inc. over blockbuster blood pressure drug Norvasc, arguing that a lower court's recent refusal to rehear the case could have “potentially wide-reaching consequences for the entire pharmaceutical research industry.”